{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:11:43Z","timestamp":1790514703532,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","mayoclinicproceedings.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.mayocp.2017.06.002","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T12:00:47Z","timestamp":1501588847000},"page":"1283-1290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Genetic Risk Assessment in Myeloproliferative Neoplasms"],"prefix":"10.1016","volume":"92","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro Maria","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.mayocp.2017.06.002_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2017.06.002_bib2","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1038\/bcj.2015.64","article-title":"Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.mayocp.2017.06.002_bib3","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.mayocp.2017.06.002_bib4","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/leu.2014.100","article-title":"Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value","volume":"28","author":"Vannucchi","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.mayocp.2017.06.002_bib5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ajh.24607","article-title":"Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management","volume":"92","author":"Tefferi","year":"2017","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.mayocp.2017.06.002_bib6","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1600-0609.2009.01214.x","article-title":"Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies","volume":"82","author":"Gangat","year":"2009","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.mayocp.2017.06.002_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/(SICI)1096-8652(199802)57:2<181::AID-AJH19>3.0.CO;2-F","article-title":"Pregnancy and thrombocythemia","volume":"57","author":"Tefferi","year":"1998","journal-title":"Am J Hematol"},{"issue":"16","key":"10.1016\/j.mayocp.2017.06.002_bib8","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mayocp.2017.06.002_bib9","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","article-title":"Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal","volume":"22","author":"Vannucchi","year":"2008","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.mayocp.2017.06.002_bib10","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/leu.2014.343","article-title":"CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis","volume":"29","author":"Finazzi","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.mayocp.2017.06.002_bib11","doi-asserted-by":"crossref","first-page":"e416","DOI":"10.1038\/bcj.2016.24","article-title":"Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations","volume":"6","author":"Barraco","year":"2016","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.mayocp.2017.06.002_bib12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2013.286","article-title":"U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.mayocp.2017.06.002_bib13","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.mayocp.2017.06.002_bib14","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","article-title":"Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.mayocp.2017.06.002_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"key":"10.1016\/j.mayocp.2017.06.002_bib16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.mayocp.2017.06.002_bib17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bjh.13260","article-title":"A\u00a0compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients","volume":"169","author":"Wassie","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.mayocp.2017.06.002_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1600-0609.2007.01003.x","article-title":"Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates","volume":"80","author":"Gangat","year":"2008","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.mayocp.2017.06.002_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1600-0609.2009.01246.x","article-title":"Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance","volume":"83","author":"Gangat","year":"2009","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1016\/j.mayocp.2017.06.002_bib20","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.mayocp.2017.06.002_bib21","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A\u00a0prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.mayocp.2017.06.002_bib22","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2017.06.002_bib23","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/sj.leu.2404500","article-title":"Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients","volume":"21","author":"Gangat","year":"2007","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.mayocp.2017.06.002_bib24","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.1038\/bcj.2016.98","article-title":"MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia","volume":"6","author":"Haider","year":"2016","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.mayocp.2017.06.002_bib25","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ajh.24338","article-title":"Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia","volume":"91","author":"Elala","year":"2016","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.mayocp.2017.06.002_bib26","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1038\/leu.2014.148","article-title":"Calreticulin mutations and long-term survival in essential thrombocythemia","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.mayocp.2017.06.002_bib27","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ajh.24293","article-title":"Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients","volume":"91","author":"Haider","year":"2016","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.mayocp.2017.06.002_bib28","doi-asserted-by":"crossref","first-page":"E296","DOI":"10.1002\/ajh.24334","article-title":"Splenomegaly and thrombosis risk in essential thrombocythemia: the Mayo Clinic experience","volume":"91","author":"Haider","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.mayocp.2017.06.002_bib29","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1038\/bcj.2015.94","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"issue":"22","key":"10.1016\/j.mayocp.2017.06.002_bib30","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.mayocp.2017.06.002_bib31","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1182\/blood-2014-08-596676","article-title":"Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia","volume":"124","author":"Finazzi","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mayocp.2017.06.002_bib32","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ajh.24377","article-title":"Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group","volume":"91","author":"Rotunno","year":"2016","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.mayocp.2017.06.002_bib33","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/leu.2016.351","article-title":"Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.mayocp.2017.06.002_bib34","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood.V128.22.3115.3115","article-title":"Abnormal karyotype and prognosis in polycythemia vera: a single center experience in 239 informative cases","volume":"128","author":"Cerquozzi","year":"2016","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.mayocp.2017.06.002_bib35","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1182\/blood-2014-06-583161","article-title":"Presence of calreticulin mutations in JAK2-negative polycythemia vera","volume":"124","author":"Bros\u00e9us","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.mayocp.2017.06.002_bib36","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/ajh.22058","article-title":"Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis","volume":"86","author":"Pardanani","year":"2011","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.mayocp.2017.06.002_bib37","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mayocp.2017.06.002_bib38","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A\u00a0prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.mayocp.2017.06.002_bib39","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mayocp.2017.06.002_bib40","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A\u00a0dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2017.06.002_bib41","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2017.06.002_bib42","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2009-08-240135","article-title":"International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis","volume":"115","author":"Hussein","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2017.06.002_bib43","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/leu.2010.234","article-title":"Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients","volume":"25","author":"Caramazza","year":"2011","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.mayocp.2017.06.002_bib44","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1182\/blood-2011-08-371096","article-title":"Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients","volume":"118","author":"Tefferi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2017.06.002_bib45","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/blood.V124.21.631.631","article-title":"Revised cytogenetic risk stratification in primary myelofibrosis: a Mayo Clinic study of 903 patients","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.mayocp.2017.06.002_bib46","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2014-07-588426","article-title":"The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mayocp.2017.06.002_bib47","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.mayocp.2017.06.002_bib48","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.mayocp.2017.06.002_bib49","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1038\/bcj.2015.90","article-title":"Validation of the differential prognostic impact of type 1\/type 1-like versus type 2\/type 2-like CALR mutations in myelofibrosis","volume":"5","author":"Guglielmelli","year":"2015","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.mayocp.2017.06.002_bib50","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.mayocp.2017.06.002_bib51","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood-2013-11-536557","article-title":"Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study","volume":"123","author":"Guglielmelli","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mayocp.2017.06.002_bib52","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.mayocp.2017.06.002_bib53","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mayocp.2017.06.002_bib54","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/leu.2010.113","article-title":"IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.mayocp.2017.06.002_bib55","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/leu.2011.253","article-title":"IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F","volume":"26","author":"Tefferi","year":"2012","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.mayocp.2017.06.002_bib56","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2012-05-429696","article-title":"SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival","volume":"120","author":"Lasho","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2017.06.002_bib57","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/leu.2009.225","article-title":"JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46\/1 haplotype is associated with inferior survival","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.mayocp.2017.06.002_bib58","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior\u00a0overall and leukemia-free survival","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.mayocp.2017.06.002_bib59","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mayocp.2017.06.002_bib60","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1200\/JCO.2011.39.0310","article-title":"Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms","volume":"30","author":"Pardanani","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.mayocp.2017.06.002_bib61","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002561961730410X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002561961730410X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T00:01:21Z","timestamp":1602633681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002561961730410X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S002561961730410X"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2017.06.002","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic Risk Assessment in Myeloproliferative Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2017.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}